Doctors Blast Rosy Research For Medtronic Bone Device

Law360, New York (June 28, 2011, 9:19 PM EDT) -- The authors of 13 industry-sponsored studies on Medtronic Inc.'s bone-growth device Infuse downplayed serious risks related to the product and failed to adequately — if at all — disclose their financial ties with the manufacturer, a study published Tuesday said.

A review of the industry-sponsored studies by The Spine Journal shows that risks of side effects were 10 to 50 times higher than originally reported in the 13 trials. Many authors of the 13 studies involving 780 patients had a financial association with the Infuse manufacturer,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.